New Results

Transthyretin-stabilizing mutation T119M is not associated with protection against vascular disease or death in the UK Biobank

Margaret M. Parker, Simina Ticau, James Butler, David Erbe, Madeline Merkel, Emre Aldinc, Gregory Hinkle, Paul Nioi
doi: https://doi.org/10.1101/771626

Article Information

doi 
https://doi.org/10.1101/771626
History 
  • September 21, 2019.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Margaret M. Parkera,
  2. Simina Ticaua,
  3. James Butlera,
  4. David Erbea,
  5. Madeline Merkela,
  6. Emre Aldinca,
  7. Gregory Hinklea and
  8. Paul Nioia,*
  1. aAlnylam Pharmaceuticals, Cambridge, MA, USA
  1. ↵*CONTACT Paul Nioi pnioi{at}alnylam.com Alnylam Pharmaceuticals, 300 3rd St., Cambridge, MA 02142, USA
Back to top
Posted September 21, 2019.
Download PDF
Email
Transthyretin-stabilizing mutation T119M is not associated with protection against vascular disease or death in the UK Biobank
Margaret M. Parker, Simina Ticau, James Butler, David Erbe, Madeline Merkel, Emre Aldinc, Gregory Hinkle, Paul Nioi
bioRxiv 771626; doi: https://doi.org/10.1101/771626
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area